Johnson & Johnson has taken part in a round for BlackThorn Therapeutics, which is targeting neurobehavioural conditions like depression or obsessive compulsive disorder.

US-based clinical-stage biopharmaceutical company BlackThorn Therapeutics closed a $40m series A round on Thursday that featured Johnson & Johnson Innovation – JJDC, the corporate venturing arm of healthcare group Johnson & Johnson. The round was led by venture capital firm Arch Venture Partners, with participation from life sciences real estate provider Alexandria Real Estate Equities,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.